2. PI3K/Akt/mTOR
  3. Akt PI3K
  4. Recilisib sodium

Recilisib sodium  (Synonyms: ON 01210 sodium)

Cat. No.: HY-101625A
Handling Instructions

Molarity Calculator

Recilisib sodium (ON 01210) is a radioprotectant, which can activate AKT, PI3K activities in cells.

For research use only. We do not sell to patients.

Recilisib sodium Chemical Structure

Recilisib sodium Chemical Structure

CAS No. : 922139-31-9

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Recilisib sodium:

Other Forms of Recilisib sodium:

Recilisib sodium Related Antibodies

Top Publications Citing Use of Products

    Recilisib sodium purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2020 Mar 15;147:79-88.  [Abstract]

    Measurement of ERK1/2 and NF-κB p65. Effect of GFP-A and Recilisib (activator of Akt) (10 μmol/L) on the expression of phosphorylated ERK1/2 in HT-29 cells. Cells are treated with 180 μg/mL GFP-A in the presence or absence of Recilisib for different durations of time.

    Recilisib sodium purchased from MedChemExpress. Usage Cited in: Environ Toxicol. 2020 Dec;35(12):1299-1307.  [Abstract]

    FaDu cells with AGK overexpression is treated with the PI3K inhibitor LY294002, and Cal27 cells with AGK knockdown is treated with PI3K activator Recilisib (50 μM). The inhibitory effect of LY294002 and promoting effects of Recilisib on PI3K/Akt signaling is confirmed by Western blot analysis.

    View All Akt Isoform Specific Products:

    View All Isoforms

    View All PI3K Isoform Specific Products:

    View All Isoforms

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Recilisib sodium (ON 01210) is a radioprotectant, which can activate AKT, PI3K activities in cells[1].

    In Vitro

    Recilisib sodium (up to 50 μM) shows a normal distribution of cells throughout the cell cycle, with a slight reduction in the number of cells in S-phase at 50 μM. Continuous exposure of Recilisib sodium (100 μM) does not result in cell death. Recilisib sodium treatment does not inhibit the colony forming potential of human bone marrow cells. Recilisib sodium provides dose dependent protection of human bone marrow cells at all three doses of IR. Recilisib sodium activates the phosphorylation of AKT and GSK3α/β in HFL cells. Recilisib sodium increases PI3K activity in HFL-1 cells and murine bone marrow cells in response to radiation exposure. Recilisib sodium treatment in combination with radiation alters the MAPK signaling pathway[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Recilisib sodium Related Antibodies
    In Vivo

    Recilisib sodium (500 mg/kg) significantly increases the rate of recovery and differentiation of primitive bone marrow myeloid progenitor cells in mice. Recilisib sodium in combination with radiation reduces CFU numbers in mice, but the Recilisib sodium-treated mice consistently retain a capability to form differentiated colonies. Recilisib sodium treated mice have a progenitor cell population that is never completely depleted by radiation exposure[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Molecular Weight

    358.77

    Formula

    C16H12ClNaO4S
    CAS No.
    SMILES

    O=C(C1=CC=C(C=C1)/C=C/S(=O)(CC2=CC=C(C=C2)Cl)=O)O[Na]
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Purity & Documentation
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Recilisib sodium Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Recilisib922139-31-9ON 01210ON01210ON-01210AktPI3KPKBProtein kinase BPhosphoinositide 3-kinaseInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Recilisib sodium
    Cat. No.:
    HY-101625A
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.